Abstract: A biological information measuring apparatus includes a biomagnetism detector configured to detect biomagnetism of a subject, the biomagnetism detector including a temperature adjustment mechanism; and a radiation detector configured to acquire emitted radiation as digital image data. The radiation detector is disposed between a measurement region of the subject and the biomagnetism detector.

Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5? terminal side of the region, (c) one or more nucleotide analogs located on 3? terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

Abstract: An anti-adhesion material comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing an anti-adhesion material comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; an anti-adhesion material kit comprising decellularized tissues and a biocompatible polymer or fibrin glue; a substitute biomembrane comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing a substitute biomembrane comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; and a substitute biomembrane kit comprising decellularized tissues and a biocompatible polymer or fibrin glue.

Abstract: Disclosed are double-stranded nucleic acid agents that can deliver a therapeutic oligonucleotide within a biological sample, and methods for using the same. In one embodiment, the double-stranded nucleic acid agent comprises a first strand comprising a first RNA region, and a second strand comprising a first DNA region, wherein said first RNA region and said first DNA region are hybridized as a RNA/DNA heteroduplex. Said first strand further comprises a nucleic acid therapeutic oligonucleotide region that is capable of being cleaved from at least one nucleotide in said first RNA region. Methods for using the double-stranded nucleic acid agents include methods for delivering the therapeutic oligonucleotide as a single strand by cleaving it from at least a portion of the first RNA region. The methods further include delivering the double-stranded nucleic acid agent and thus the therapeutic oligonucleotide to a target site within the body of a treatment subject.

Abstract: The object of the present invention is to provide a nucleic acid agent that can be efficiently delivered to the nervous system, particularly the central nervous system to which the BBB mechanism prevents drug delivery, and can produce an antisense effect on a target transcriptional product at the delivered site, and a composition comprising the same. Provided is a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand capable of hybridizing to part of a target transcriptional product, and has an antisense effect on the target transcriptional product, to a second nucleic acid strand comprising a base sequence complementary to the first nucleic acid strand, and is bound to tocopherol or an analog thereof, cholesterol or an analog thereof, or a substituted or unsubstituted C1-30 alkyl group, a substituted or unsubstituted C2-30 alkenyl group, or a substituted or unsubstituted C1-30 alkoxy group.

Abstract: A biometric information display device includes a display controller configured to display a morphological image indicative of a morphology of a subject, on a display, an input controller configured to receive a designation of a specified position on the morphological image, a pathway generating section configured to generate a pathway based on the specified position on the morphological image, and a current extracting section configured to extract current components at a plurality of positions along the pathway, based on current information reconstructed based on magnetic field measurement data generated by the subject. The display controller displays the current components extracted along the pathway on the display.

Abstract: The present invention provides an antisense nucleic acid medicine that can modulate expression of a target transcriptional product in an ischemic site of a subject. The present invention also provides a composition for modulating expression of a target transcriptional product in an ischemic site of a subject, having a nucleic acid complex formed by annealing together a first nucleic acid strand having an antisense oligonucleotide region with respect to the target transcriptional product, and a lipid-conjugated second nucleic acid strand having a complementary region that is complementary to at least part of the first nucleic acid strand.

Abstract: To provide a compound which enables treatment or prevention of spinocerebellar ataxia, analyses were carried out based on a screening using a spinocerebellar ataxia type 1 (SCA1) fly model and on the like. As a result, the following proteins ameliorating the pathology of spinocerebellar ataxia were identified: RPA1, PNKP, XRCC3, XRCC4, CCNH, POLE, POLH, and PER1. On the other hand, the following proteins aggravating the pathology were identified: CHK1, LIG3, FEN1, LIG1, ERCC5, XAB2, ERCC2, DMC1, RECQL5, MUS81, EME1, SPO11, and BLM. In addition, it has been revealed that ATXN1, which is a cause of SCA1, binds to RPA1, BRCA1, and BRCA2, and suppresses the activities of these proteins, so that the above-described pathology is caused.

Abstract: A nerve stimulating apparatus includes a plurality of stimulating units configured to respectively apply stimuli to a plurality of nerve regions branching from a particular nerve region of a living body, and a stimulation timing controller configured to set generating timings of respectively generating the stimuli at the plurality of stimulating units. The stimulation timing controller sets the generating timings of generating the stimuli at the plurality of stimulating units based on response results of the particular nerve region, the response results being obtained in response to the stimuli that are respectively generated at the plurality of stimulating units and that are respectively applied to the plurality of nerve regions, and the response results being measured by a biometric information measuring apparatus that measures biometric information.

Abstract: A biomagnetism measurement device includes a tubular body, an inflatable portion inflatable upon supply of gas, and a magnetic sensor portion that detects a magnetic field from outside the tubular body. The inflatable portion is located at a required region of the tubular body, and the magnetic sensor portion is fixed to an inner wall of the inflatable portion. The tubular body and the inflatable portion include the same material, and the wall thickness of the inflatable portion is thinner than that of the tubular body.

Abstract: It has been found that efficient screening for a compound having anticancer activity can be achieved by selecting a compound having activity to induce alternative autophagy using, as an index, formation of fluorescent bright spots due to aggregation of a lysosomal protein to which a fluorescent protein is attached in cells expressing the lysosomal protein.

Abstract: A magnetic measuring apparatus includes an inclination gantry including a mount surface and an inclined surface that is inclined with respect to the mount surface, a cryostat disposed on the inclined surface, a cryocooling system connected to the cryostat, a sensor tube connected to the cryostat and including a curved surface that does not curve in a predetermined direction and curves in a direction orthogonal to the predetermined direction such that a center of the curved surface protrudes with respect to side edges of the curved surface, and a magnetic sensor that measures biomagnetism and is housed in the sensor tube such that a sensor surface of the magnetic sensor faces the curved surface. The sensor surface is inclined with respect to the mount surface in a direction that is the same as a direction in which the inclined surface is inclined.

Abstract: The present invention provides a vesicle, a conjugate, a composition comprising the vesicle or the conjugate, for use in delivering a drug to the brain, and a method for administering the same. The composition of the present invention is a composition for administration to a subject according to a dosing regimen, comprising a carrier for drug delivery, wherein the dosing regimen comprises administering the composition to a subject who has been fasted or caused to have hypoglycemia and inducing an increase in blood glucose level in the subject, and the carrier is modified at the outer surface thereof with a GLUT1 ligand.

Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

Abstract: Removable denture data of a removable denture is produced, and disk frame data of a disk frame in which the removable denture is accommodated is produced, thereby building the disk frame based on the disk frame data. Next, a resin disk in which artificial teeth are embedded is produced by arranging the artificial teeth in the disk frame and curing a base resin, and a denture base is milled by milling the resin disk based on the removable denture data, thereby manufacturing the removable denture in which a base side of the artificial teeth is embedded in the denture base. As a result, artificial teeth having an excellent aesthetics may be used, it is possible to firmly join the artificial teeth and the denture base to each other, and it is possible to manufacture a removable denture with a favorable restoration accuracy of the artificial teeth.

Abstract: An object of the invention is to provide a low toxicity antisense nucleic acid medicine that can modulate expression of a target transcriptional product in the central nervous system and other sites of a subject. Provided is a low toxicity composition for modulating expression of a target transcriptional product in a site such as the central nervous system of a subject, having a nucleic acid complex formed by annealing together a first nucleic acid strand having an antisense oligonucleotide region with respect to the target transcriptional product, and a second nucleic acid strand having a complementary region that is complementary to at least part of the first nucleic acid strand.

Abstract: Provided is a method for detecting a neurodegenerative disease selected from the group consisting of human Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD), and amyotrophic lateral sclerosis (ALS) with high sensitivity and high specificity.

Abstract: A biological data processing apparatus includes an addition averaging processor configured to perform an addition averaging process on measurement data of a magnetic field generated by a living body; an estimator configured to perform an estimation process of estimating an intensity of an action current within the living body based on addition average data acquired by the addition averaging processor; a start instruction acceptor configured to accept a start instruction to start the estimation process by the estimator while measurement of the magnetic field is being performed; and a display configured to display an estimation result obtained by the estimator in response to the start instruction.

Abstract: A device for biological material detection includes a substrate; a through-hole through which a biological material to be tested passes, the through-hole being formed in the substrate; a molecule that interacts with the biological material to be tested passing through, the molecule being formed in the through-hole; a first chamber member that forms, with at least the surface including the through-hole on one surface side of the substrate, a first chamber to be filled with electrolyte; and a second chamber member that forms, with at least the surface including the through-hole on the other surface side of the substrate, a second chamber to be filled with electrolyte. The biological material to be tested is identified by the waveform of the ion current (passage time, shape, etc.) when the biological material to be tested passes through the through-hole.

Abstract: The present inventors have found microRNAs which are strongly associated with stabilization of NRF2 in tumors, and an object of the present invention is to provide means for utilizing such miRNAs for the diagnosis and treatment of cancer. The inventors conducted screening of 470 microRNAs in a microRNA library by use of HeLa cells. As a result, 8 miRNAs each exhibiting a large decrease in miRNA activity as compared with a control miRNA, and 8 miRNAs each exhibiting a large increase in miRNA activity as compared with a control miRNA, were identified. The inventors have found that the NRF2 activation in the living body, in particular tumor cells, can be detected by use of the thus-identified miRNAs, whereby malignancy of a tumor, or the like can be differentiated. The inventors have also found that a nucleic acid including a miRNA sequence associated with reduction in the aforementioned ARE activity can be used as a cancer therapeutic agent.